Neuroimaging and blood markers as indicators of ketamine efficacy in treatment resistant depression
Description of the granted funding
Major Depressive Disorder (MDD) is a highly disabling chronic disease where 30% of patients show treatment resistance (TRD), rendering it the leading cause of disability worldwide (WHO 2018). The FDA approved Spravato (esketamine) nasal spray for the treatment of depression in TRD patients in March, 2019 leading to increased patient requests and a need for clinical decision support. Increased demand for Ketamine for TRD needs to be balanced by relevant side effects and potential risk of abuse. Currently, clinical decisions lack estimation on patients' individual benefit which is only expected to see responses in 50%. This project aims to validate antidepressant response biomarkers focusing on peripheral and central mechanisms involved in synaptic plasticity and BDNF. Focusing on a fundamental pathophysiological signature, we will contribute to stratification and response monitoring using the latest technological advances in clinical research in TRD, proteomics and neuroimaging.
Show moreStarting year
2020
End year
2024
Granted funding
Funder
Research Council of Finland
Funding instrument
Kansainvälinen yhteisrahoitteinen ohjelma
Other information
Funding decision number
334776
Fields of science
Biomedicine
Research fields
Biolääketieteet
Identified topics
brain, neuroscience